Anti-CD4 Antibody (OKT-4) 

Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human CD4. Anti-CD4 Antibody (OKT-4) can deplete T cells. Anti-CD4 Antibody (OKT-4) can be used for the researches of cancer, infection and immunology, such as melanoma and adenovirus infection^[1][2].

Mouse IgG2b kappa

Mouse IgG2b kappa, Isotype Control

Human

CD4

Anti-CD4 Antibody (OKT-4) (250 μg, i.p., every 2 days) depletes CD4 T cells and diminishes antitumor response of anti-PD-1 antibody in MC38/YUMM2.1 tumor C57BL/6 mice^[1].
Anti-CD4 Antibody (OKT-4) (100 μg, i.p., daily for 3 days) depletes T cells and reduces virus clearance in adenovirus-infected humanized HIS-A2/DR1 mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

920  [NCBI]

P01730

in vitro T cell stimulation/activation; in vivo CD4+ T cell depletion in humanized mice; Flow cyto

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

Liquid

Colorless to light yellow

[Anti-CD4 Antibody (OKT-4)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Flow Cytometry analysis of THP-1 cells labelling CD4 (red) with CD4 Antibody (anti-CD4) (HY-P990861). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Mouse IgG H&L (AF488) (HY-P8005) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃.Mouse IgG2b kappa isotype Control (HY-P99982, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Homet Moreno B, et al. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunol Res. 2016 Oct;4(10):845-857.  [Content Brief]

  [2]. Billerbeck E, et al. Characterization of human antiviral adaptive immune responses during hepatotropic virus infection in HLA-transgenic human immune system mice. J Immunol. 2013 Aug 15;191(4):1753-64.  [Content Brief]